WallStreetZenWallStreetZen

NASDAQ: RAPT
Rapt Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for RAPT

Based on 3 analysts offering 12 month price targets for Rapt Therapeutics Inc

Min Forecast
$1.00-3.85%
Avg Forecast
$5.67+444.9%
Max Forecast
$10.00+861.54%

Should I buy or sell RAPT stock?

Based on 3 analysts offering ratings for Rapt Therapeutics Inc.

Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 66.67%
Hold
1 analysts 33.33%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although RAPT's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates RAPT as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their RAPT stock forecasts and price targets.

RAPT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-05-22
lockedlocked$00.00+00.00%2025-05-22
lockedlocked$00.00+00.00%2025-03-10

1 of 1

Forecast return on equity

Is RAPT forecast to generate an efficient return?

Company
-44.75%
Industry
140.91%
Market
90.47%
RAPT's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is RAPT forecast to generate an efficient return on assets?

Company
-42.32%
Industry
32.45%
RAPT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

RAPT earnings per share forecast

What is RAPT's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$0.38
Avg 2 year Forecast
-$0.40
Avg 3 year Forecast
-$0.52

RAPT revenue forecast

What is RAPT's revenue in the next 2 years based on estimates from 1 analyst?

Avg 1 year Forecast
$36.3M
Avg 2 year Forecast
$127.2M

RAPT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
RAPT$1.04$5.67+444.90%Buy
EPRX$3.86N/AN/A
IKT$1.86N/AN/A
NMRA$0.85$6.00+610.06%Hold
KYTX$3.22$12.50+288.20%Strong Buy
View Top Biotech Stocks

Rapt Therapeutics Stock Forecast FAQ

Is Rapt Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: RAPT) stock is to Buy RAPT stock.

Out of 3 analysts, 0 (0%) are recommending RAPT as a Strong Buy, 2 (66.67%) are recommending RAPT as a Buy, 1 (33.33%) are recommending RAPT as a Hold, 0 (0%) are recommending RAPT as a Sell, and 0 (0%) are recommending RAPT as a Strong Sell.

If you're new to stock investing, here's how to buy Rapt Therapeutics stock.

What is RAPT's earnings growth forecast for 2025-2027?

(NASDAQ: RAPT) Rapt Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.33%.

Rapt Therapeutics's earnings in 2025 is -$116,509,000.On average, 3 Wall Street analysts forecast RAPT's earnings for 2025 to be -$49,833,148, with the lowest RAPT earnings forecast at -$56,884,135, and the highest RAPT earnings forecast at -$44,978,153. On average, 3 Wall Street analysts forecast RAPT's earnings for 2026 to be -$52,915,474, with the lowest RAPT earnings forecast at -$80,696,098, and the highest RAPT earnings forecast at -$31,749,285.

In 2027, RAPT is forecast to generate -$68,128,673 in earnings, with the lowest earnings forecast at -$80,696,098 and the highest earnings forecast at -$55,561,248.

What is RAPT's revenue growth forecast for 2029-2030?

(NASDAQ: RAPT) Rapt Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.

Rapt Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast RAPT's revenue for 2029 to be $4,802,079,302, with the lowest RAPT revenue forecast at $4,802,079,302, and the highest RAPT revenue forecast at $4,802,079,302.

In 2030, RAPT is forecast to generate $16,820,506,425 in revenue, with the lowest revenue forecast at $16,205,364,035 and the highest revenue forecast at $17,435,648,815.

What is RAPT's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: RAPT) forecast ROA is -42.32%, which is lower than the forecast US Biotechnology industry average of 32.45%.

What is RAPT's Price Target?

According to 3 Wall Street analysts that have issued a 1 year RAPT price target, the average RAPT price target is $5.67, with the highest RAPT stock price forecast at $10.00 and the lowest RAPT stock price forecast at $1.00.

On average, Wall Street analysts predict that Rapt Therapeutics's share price could reach $5.67 by May 22, 2026. The average Rapt Therapeutics stock price prediction forecasts a potential upside of 444.9% from the current RAPT share price of $1.04.

What is RAPT's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: RAPT) Rapt Therapeutics's current Earnings Per Share (EPS) is -$2.48. On average, analysts forecast that RAPT's EPS will be -$0.38 for 2025, with the lowest EPS forecast at -$0.43, and the highest EPS forecast at -$0.34. On average, analysts forecast that RAPT's EPS will be -$0.40 for 2026, with the lowest EPS forecast at -$0.61, and the highest EPS forecast at -$0.24. In 2027, RAPT's EPS is forecast to hit -$0.52 (min: -$0.61, max: -$0.42).

What is RAPT's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: RAPT) forecast ROE is -44.75%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.